glp-1 and medicare What is the Bridge? Bridge is a new CMS program starting on July 1 that may help eligible Medicare patients access certain GLP-1 obesity medications. If you are on Medicare Clinical Capsules: Navigating the Medicare

Only vitamin E supplementation significantly increased the overall rate of improvement in histological abnormalities that characterize MASH on liver biopsies (i.e., hepatocellular ballooning, steatosis, and lobular inflammation) (98)

Genetic testing can aid in the differential diagnosis of PFIC [73], enable patients to benefit from innovative therapies [16], and provide appropriate genetic counselling to parents of affected children

Given the relationship between diabetes and chronic kidney disease, it should come as no surprise that GLP1 receptor agonists can positively impact the clinical trajectory of those with kidney disease

It is indicated for adults with obesity who tolerate 2.4mg and require further weight reduction

Very exciting to see what is next